|
|
Combining Locoregional and Systemic Therapy for Challenging HCC Cases
Target Audience
This educational activity is intended for interventional oncologyists physicians, nurses, and other members of the health care team who care for patients with hepatocellular carcinoma (HCC)
Program Overview
This activity focuses on challenges in the management of HCC using the latest clinical data supporting locoregional therapy, and on strategies for greater collaboration amongst the multidisciplinary teams in community vs academic settings.
Learning Objectives
Upon c... |
|
|
Dermatological Compounding
September 13th- 14th, 2024
DERMATOLOGICAL COMPOUNDING is an accredited 15 hour (1.5 CEUs) knowledge / application-based course that comprises a blend of didactic lectures for theoretical understanding and laboratory activities for practical application. This approach enhances an already established skill of compounding, providing you with a more in-depth insight into the field. However, it is recommended for participants to have a solid understanding of fundamental compounding techniques an... |
|
|
Nursing Management of Tumor Lysis Syndrome
STATEMENT OF NEED
Tumor lysis syndrome (TLS) is an oncological emergency that occurs when massive tumor lysis causes the rapid release of intracellular components into the bloodstream. Electrolyte imbalances characterized by hyperuricemia, hyperkalemia, hyperphosphatemia, and hypocalcemia may be severe enough to cause acute renal failure, cardiac arrhythmias, seizures, and even death. Current advances in cancer therapies can increase the incidence of TLS; therefore, identification of patien... |
|
|
Therapeutic Advancements for the Treatment of High-Risk MDS: Future Opportunities to Improve Patient Survival and Quality of Life
Stay up to date on the evolving risk classification for myelodysplastic syndromes (MDS) and current treatment guidelines for patients with high-risk disease in this self-directed education with leading oncology experts. Expert commentary from Courtney DiNardo, MD from MD Anderson Cancer Center and Dr. Dan Pollyea from the University of Colorado School of Medicine provides insights on emerging therapies that could soon improve management of high-risk MDS. Be ready to incorporate these emerging ... |
|
|
Across the Compendium: Practical Pathways to Integrate Bispecific Antibodies Into Care for Patients With Relapsed/Refractory Multiple Myeloma
As the armamentarium of therapies for relapsed/refractory multiple myeloma (R/R MM) expands, several factors, including previous therapy, treatment-related toxicity, and comorbidities must be considered as part of clinical decision making. To assist the multidisciplinary treatment team in these efforts, and ensure patients are receiving cutting-edge cancer care, this immersive digital practice guide highlights best practices, clinical pearls, and strategies to overcome pitfalls in the administ... |
|